<DOC>
	<DOCNO>NCT01024335</DOCNO>
	<brief_summary>The goal two-year study test efficacy dronabinol adjunct maintenance treatment naltrexone opioid-dependent individual . We hypothesize administer dronabinol detoxification first week naltrexone treatment lead improve naltrexone tolerability , result good naltrexone compliance treatment retention , ultimately reduction opioid use relapse rate .</brief_summary>
	<brief_title>Dronabinol Naltrexone Treatment Opioid Dependence</brief_title>
	<detailed_description>The goal two-year study test efficacy dronabinol adjunct maintenance treatment naltrexone opioid-dependent individual . We propose randomize , double-blind , placebo control , parallel-groups , 8 week study relapse prevention opioid-dependent individual . Participants randomize one two condition ( 1 ) Naltrexone Placebo ( N=20 ) ( 2 ) Naltrexone dronabinol 15 mg bid ( N=40 ) . Treatment delivered outpatient set except initial phase inpatient detoxification , last 8 day . A long-acting , injectable form naltrexone 380 mg ( Vivitrol ) administer per month ( total two injection ) , dronabinol placebo take daily . In addition , patient receive psychosocial intervention include element motivational interview cognitive-behavioral relapse prevention therapy . The primary aim test efficacy dronabinol improve tolerability naltrexone induction reduce attrition detoxification first two month naltrexone treatment . The primary outcome severity opiate withdrawal craving . The secondary outcome retention treatment study 's end .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Adult , aged 1860 . 2 . Meets Diagnostic Statistical Manual IV criterion current opiate dependence disorder least six month duration , support positive urine opiate positive naloxone challenge test diagnosis unclear . 3 . Have history marijuana use ( 30 occasion lifetime ) 4 . Voluntarily seek treatment opioid dependence 5 . In otherwise good health base complete medical history , physical examination , vital sign measurement , ECG , laboratory test ( hematology , blood chemistry , urinalysis ) within normal range . 6 . Able give inform consent . 1 . Physiologically dependent alcohol sedativehypnotics impend withdrawal . 2 . Patients meet current criterion cannabis abuse dependence , use cannabis week prior study entry document positive toxicology 3 . Current Diagnostic Statistical Manual IV criterion substance use disorder . Exceptions include cannabis abuse dependence , nicotine dependence , cocaine abuse dependence , alcohol abuse alcohol dependence without physiological dependence long opioid dependence primary disorder . Alcohol dependence physiological dependence exclusionary . 4 . Significant current suicidal risk 1 suicide attempt within past year 5 . History accidental drug overdose last three year define episode opioidinduced unconsciousness incapacitation , whether medical treatment seek receive . 6 . Positive serum pregnancy test , lactation , unwillingness use satisfactory method birth control 7 . Active psychiatric disorder might interfere participation make participation hazardous , include Diagnostic Statistical Manual IV organic mental disorder , psychotic disorder , bipolar disorder mania 8 . History allergic reaction , adverse reaction , sensitivity study medication . 9 . Acute hepatitis serum glutamicoxaloacetic transaminase serum glutamicpyruvic transaminase &gt; 3 time upper end laboratory normal range ( chronic hepatitis acceptable find naltrexone treatment well tolerate safe among patient chronic hepatitis ) 10 . Currently prescribe regularly take opiate chronic pain medical illness . 11 . Current participation methadone maintenance treatment program and/or regular use illicit methadone ( &gt; 30 mg per week ) . 12 . Current participation another intensive psychotherapy substance abuse treatment program participation another treatment study . 13 . Concurrent treatment psychotropic medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>opioid dependence</keyword>
	<keyword>naltrexone</keyword>
	<keyword>vivitrol</keyword>
	<keyword>dronabinol</keyword>
	<keyword>marinol</keyword>
</DOC>